BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20598882)

  • 1. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.
    He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Weinberg DH; Macneil T; Tang R; Strack AM; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4399-405. PubMed ID: 20598882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity.
    He S; Ye Z; Dobbelaar PH; Bakshi RK; Hong Q; Dellureficio JP; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Reibarkh M; Holmes MA; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Strack AM; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6524-32. PubMed ID: 20933410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist.
    He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Tsou NN; Ball RG; Cashen DE; Martin WJ; Weinberg DH; Macneil T; Tang R; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Strack AM; Fong TM; Macintyre DE; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2106-10. PubMed ID: 20207541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.
    Nargund RP; Strack AM; Fong TM
    J Med Chem; 2006 Jul; 49(14):4035-43. PubMed ID: 16821763
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor.
    Chen C; Jiang W; Tran JA; Tucci FC; Fleck BA; Markison S; Wen J; Madan A; Hoare SR; Foster AC; Marinkovic D; Chen CW; Arellano M; Saunders J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):129-36. PubMed ID: 18032040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.
    Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.
    Tian X; Switzer AG; Derose SA; Mishra RK; Solinsky MG; Mumin RN; Ebetino FH; Jayasinghe LR; Webster ME; Colson AO; Crossdoersen D; Pinney BB; Farmer JA; Dowty ME; Obringer CM; Cruze CA; Burklow ML; Suchanek PM; Dong L; Dirr MK; Sheldon RJ; Wos JA
    J Med Chem; 2008 Oct; 51(19):6055-66. PubMed ID: 18771254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocortin-4 receptor agonists for the treatment of obesity.
    Boyce RS; Duhl DM
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1063-71. PubMed ID: 15535427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands.
    Hong Q; Bakshi RK; Dellureficio J; He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Tang R; Kalyani RN; Macneil T; Vongs A; Rosenblum CI; Weinberg DH; Peng Q; Tamvakopoulos C; Miller RR; Stearns RA; Cashen D; Martin WJ; Chen AS; Metzger JM; Chen HY; Strack AM; Fong TM; Maclntyre E; Van der Ploeg LH; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4483-6. PubMed ID: 20598533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of trans-4-(4-chlorophenyl)pyrrolidine-3-carboxamides of piperazinecyclohexanes as ligands for the melanocortin-4 receptor.
    Chen CW; Tran JA; Fleck BA; Tucci FC; Jiang W; Chen C
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6825-31. PubMed ID: 17964151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.
    Liu KK; Lefker BA; Dombroski MA; Chiang P; Cornelius P; Patterson TA; Zeng Y; Santucci S; Tomlinson E; Gibbons CP; Marala R; Brown JA; Kong JX; Lee E; Werner W; Wenzel Z; Giragossian C; Chen H; Coffey SB
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2365-9. PubMed ID: 20202843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.
    Yu M; Lizarzaburu M; Beckmann H; Connors R; Dai K; Haller K; Li C; Liang L; Lindstrom M; Ma J; Motani A; Wanska M; Zhang A; Li L; Medina JC
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1758-62. PubMed ID: 20137933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
    Suzuki T; Kameda M; Ando M; Miyazoe H; Sekino E; Ito S; Masutani K; Kamijo K; Takezawa A; Moriya M; Ito M; Ito J; Nakase K; Matsushita H; Ishihara A; Takenaga N; Tokita S; Kanatani A; Sato N; Fukami T
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5339-45. PubMed ID: 19683441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents.
    Roth JD; D'Souza L; Griffin PS; Athanacio J; Trevaskis JL; Nazarbaghi R; Jodka C; Athanacio J; Hoyt J; Forood B; Parkes DG
    Diabetes Obes Metab; 2012 Jul; 14(7):608-15. PubMed ID: 22276636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Hagmann WK
    Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.
    Pierson PD; Fettes A; Freichel C; Gatti-McArthur S; Hertel C; Huwyler J; Mohr P; Nakagawa T; Nettekoven M; Plancher JM; Raab S; Richter H; Roche O; Rodríguez Sarmiento RM; Schmitt M; Schuler F; Takahashi T; Taylor S; Ullmer C; Wiegand R
    J Med Chem; 2009 Jul; 52(13):3855-68. PubMed ID: 19456097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.
    Hong Q; Bakshi RK; Palucki BL; Park MK; Ye Z; He S; Pollard PG; Sebhat IK; Liu J; Guo L; Cashen DE; Martin WJ; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Strack AM; Fong TM; MacIntyre DE; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2330-4. PubMed ID: 21439820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
    Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.